Navigation Links
Bone marrow mononuclear stem cells show no new gains in heart function says TIME study
Date:11/18/2013

MINNEAPOLIS, MN November 18, 2013 New data reported by the Cardiovascular Cell Therapy Research Network (CCTRN) at the 2013 Scientific Sessions of the American Heart Association in Dallas showed that the use of bone marrow mononuclear stem cells (BMCs) did not improve heart function significantly more at one year than at six months. While there was measurable decrease in the size of scar tissue at six and 12 months, stem cells administered as a part of the TIME (Transplantation In Myocardial Infarction Evaluation) study did not improve overall heart functionality. The results were presented by Jay Traverse, MD of the Minneapolis Heart Institute Foundation on Monday, Nov. 18.

"While there are no safety issues with BMC's, the resulting reduction in scar tissue (infarct size) at six months and at one year and the small improvement in left-ventricular function was no different than a placebo, suggesting that these types of stem cells would appear to be of low therapeutic efficacy, " stated Jay Traverse, MD, of the Minneapolis Heart Institute Foundation. "At this early stage of stem cell therapy research investigating viable post-heart attack strategies, our study and others suggest that we should look at other, more potent stem cells as a means to improving functionality following a heart attack." Traverse noted that this is one of the largest serial cardiac MRI studies examining the changes in left-ventricular function following a heart attack.

In this analysis, the administration of BMC's following moderate to large anterior STelevated myocardial infarction (STEMIs) was not associated with improved recovery of global and regional left ventricular (LV) function at one year compared to placebo. Levels of left ventricular ejection fraction (LVEF) increased from baseline to six months but did not improve further between six months and one year in either the BMC or the placebo group. On average, infarct size decreased in the BMC and placebo groups
'/>"/>

Contact: Steve Goodyear
sgoodyear@mhif.org
612-863-1654
Minneapolis Heart Institute Foundation
Source:Eurekalert

Page: 1 2

Related biology news :

1. Newly identified bone marrow stem cells reveal markers for ALS
2. Type 2 diabetes patients transplanted with own bone marrow stem cells reduces insulin use
3. Researchers discover brain cancer treatment using genetic material from bone marrow cells
4. Scientists find bone-marrow environment that helps produce infection-fighting T and B cells
5. Bone marrow cells used in bladder regeneration
6. Bone marrow stem cells do not improve short-term recovery after heart attack
7. Study results: Adult stem cells from bone marrow
8. Autologous bone marrow-derived mononuclear cell transplants can reduce diabetic amputations
9. Cell therapy using patients own bone marrow may present option for heart disease
10. Bone marrow transplant arrests symptoms in model of Rett syndrome
11. Salk scientists for the first time generate mini-kidney structures from human stem cells
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/27/2015)... , July 27, 2015  Synaptics Inc. ... human interface solutions, today announced that Huawei has ... touchscreen solution for its stylish smartwatch. Huawei chose ... proven reliability, low power and highly responsive human ... finger. Huawei designers also required a classic round ...
(Date:7/27/2015)...   Zynx Health ™, the market leader ... today announced that its ZynxCarebook ™ mobile ... smartphones and tablets. With this expansion, care team ... ZynxCarebook to securely exchange messages and share assessments ... to other care settings, and improve clinical outcomes ...
(Date:7/23/2015)... Aware, Inc. (NASDAQ: AWRE ), a leading supplier of ... second quarter ended June 30, 2015.  Revenue ... decrease of 33% compared to $6.8 million in the same ... 2015 was $0.3 million, or $0.01 per diluted share, which ... the same period a year ago.  Lower ...
Breaking Biology News(10 mins):Synaptics Touchscreen Solution Powers New Huawei Watch 2Synaptics Touchscreen Solution Powers New Huawei Watch 3Zynx Health Adds Android Device Support to ZynxCarebook Solution 2Zynx Health Adds Android Device Support to ZynxCarebook Solution 3Aware, Inc. Reports Second Quarter 2015 Financial Results 2Aware, Inc. Reports Second Quarter 2015 Financial Results 3Aware, Inc. Reports Second Quarter 2015 Financial Results 4Aware, Inc. Reports Second Quarter 2015 Financial Results 5Aware, Inc. Reports Second Quarter 2015 Financial Results 6
... Looking into the brain is yielding vital clues to ... being presented today at the Seventh International Conference on ... held at 12:15 p.m., Thursday, June 7, have helped ... treatment of the disease. , The first study, presented ...
... crops may contribute to increased productivity in sustainable agriculture, ... 8 issue of the journal Science. The study ... field experiments all over the world, involving corn and ... insecticidal properties. The research was conducted by scientists ...
... In a way, nanotubes are nature’s smallest candles. , These ... so small that it takes about 100,000 laid side-by-side to ... last five years, scientists have discovered that some individual nanotubes ... in light. Some glow brightly. Others glow dimly. Some glow ...
Cached Biology News:Brain holds clues to bipolar disorder 2New study finds genetically engineered crops could play a role in sustainable agriculture 2Brightening prospects of using fluorescent nanotubes in medical applications 2Brightening prospects of using fluorescent nanotubes in medical applications 3
(Date:7/24/2015)... -- Ryan & Maniskas, LLP that a class ... for the Northern District of California ... common stock of Avalanche Biotechnologies, Inc. ("Avalanche" or the "Company") ... 15, 2015, inclusive (the "Class Period"). Avalanche shareholders ... for appointment as a lead plaintiff of the Class.  If ...
(Date:7/24/2015)... Origin Agritech Limited (NASDAQ GS: SEED) ("Origin", or the "Company"), ... , today announced that the Company will report results ... 2015, before the market opens on Wednesday, August 5th, 2015. ... 5th, 2015, at 9:00 a.m. ET / 9:00 p.m. ... participate in the call, please dial the following numbers approximately ...
(Date:7/23/2015)... ... July 23, 2015 , ... The health and wellness of brain tumor ... of a brain tumor diagnosis. The American Brain Tumor Association presents interactive sessions that ... and Family Conference, July 24-25 in Chicago. , “We have understood for a ...
(Date:7/23/2015)... ... July 23, 2015 , ... The Pittcon 2016 Program ... S. Mosher Professor of Chemistry and Professor, by courtesy, of Applied Physics at Stanford ... Detection in Solids Led to Super-Resolution Nanoscopy in Cells and Beyond” , Dr. ...
Breaking Biology Technology:Ryan & Maniskas, LLP Announces Class Action Lawsuit Against Avalanche Biotechnologies, Inc. 2Ryan & Maniskas, LLP Announces Class Action Lawsuit Against Avalanche Biotechnologies, Inc. 3Origin Agritech Limited to Announce Third Quarter Fiscal 2015 Unaudited Financial Results on August 5th, 2015 2Origin Agritech Limited to Announce Third Quarter Fiscal 2015 Unaudited Financial Results on August 5th, 2015 3Reframing the Caregiver and Patient Mindset: Coping with the ‘New Normal’ 2Reframing the Caregiver and Patient Mindset: Coping with the ‘New Normal’ 3The 2014 Nobel Prize in Chemistry Recipient W. E. Moerner, to Deliver Wallace H. Coulter Lecture at Pittcon 2016 2The 2014 Nobel Prize in Chemistry Recipient W. E. Moerner, to Deliver Wallace H. Coulter Lecture at Pittcon 2016 3
... Company to Hold a Conference Call Tomorrow (Tuesday) at 8:30 am ... ... September 10 XTL,Biopharmaceuticals Ltd. (NASDAQ: XTLB ; LSE: XTL; ... of Bicifadine - a serotonin,and norepinephrine reuptake inhibitor (SNRI) - for ...
... LONDON, Sept. 7 Chiltern, a leading global ... Richard Schulz,Chiltern,s Country Manager for the Czech Republic, ... The award ceremony was held in,London,s historic Gibson ... peers by a panel of judges who,reviewed his ...
... On Thursday, October,18, 2007, Wyeth (NYSE: WYE ) ... Company will hold a one-hour conference call with,research analysts ... Interested,investors and others may listen to the call live ... may be accessed by visiting our website,at http://www.wyeth.com ...
Cached Biology Technology:XTL Biopharmaceuticals Initiates Phase IIb Clinical Trial of Bicifadine for the Treatment of Diabetic Neuropathic Pain 2XTL Biopharmaceuticals Initiates Phase IIb Clinical Trial of Bicifadine for the Treatment of Diabetic Neuropathic Pain 3XTL Biopharmaceuticals Initiates Phase IIb Clinical Trial of Bicifadine for the Treatment of Diabetic Neuropathic Pain 4XTL Biopharmaceuticals Initiates Phase IIb Clinical Trial of Bicifadine for the Treatment of Diabetic Neuropathic Pain 5XTL Biopharmaceuticals Initiates Phase IIb Clinical Trial of Bicifadine for the Treatment of Diabetic Neuropathic Pain 6XTL Biopharmaceuticals Initiates Phase IIb Clinical Trial of Bicifadine for the Treatment of Diabetic Neuropathic Pain 7Richard Schulz Receives the Coveted GCPj Award for Best Clinical Researcher of the Year 2
No description available in Ensembl Antigen: Recombinant Protein Epitope Signature Tag (PrEST)....
... atoms at the 9, 10, 12, and 13 ... internal standard for the quantification of 9(S)-HODE by ... the lipoxygenation of linoleic acid in both plants ... plaques, as an esterified component of membrane phospholipids ...
... 9(S)-HODE-d4 contains 4 deuterium atoms at the ... intended for use as an internal standard for ... spectrometry. 9(S)-HODE is produced by the lipoxygenation of ... has been detected in atherosclerotic plaques, as an ...
12(S)-HETE-d8 is used as an internal standard for the quantification of 12(S)-HETE by stable isotope dilution mass spectrometry....
Biology Products: